UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000061725
Receipt number R000070645
Scientific Title A prospective observational study evaluating changes in oral and nasal exhaled nitric oxide (NO) before and after epipharyngeal abrasive therapy (EAT) in patients with chronic nasopharyngitis
Date of disclosure of the study information 2026/06/01
Last modified on 2026/05/28 21:32:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate changes in exhaled nitric oxide (NO) before and after treatment in patients with chronic nasopharyngitis

Acronym

EAT-NO Study

Scientific Title

A prospective observational study evaluating changes in oral and nasal exhaled nitric oxide (NO) before and after epipharyngeal abrasive therapy (EAT) in patients with chronic nasopharyngitis

Scientific Title:Acronym

EAT-NO Study

Region

Japan


Condition

Condition

Chronic nasopharyngitis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to prospectively evaluate changes in oral and nasal exhaled nitric oxide (NO) before and after epipharyngeal abrasive therapy (EAT) in patients with chronic nasopharyngitis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in oral exhaled nitric oxide (NO) before and after epipharyngeal abrasive therapy (EAT) in patients with chronic nasopharyngitis (difference between baseline and after 12 sessions of EAT)

Key secondary outcomes

Changes in nasal exhaled nitric oxide (NO) before and after epipharyngeal abrasive therapy (EAT)

Association between changes in oral and nasal exhaled nitric oxide (NO) and clinical parameters (endoscopic findings score and symptom visual analog scale [VAS])


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients diagnosed with chronic nasopharyngitis
Age 15 years or older
Patients initiating epipharyngeal abrasive therapy (EAT)
Written informed consent obtained

Key exclusion criteria

Patients with acute upper respiratory infection
Patients with acute exacerbation of asthma
Patients unable to perform exhaled NO measurement

Target sample size

45


Research contact person

Name of lead principal investigator

1st name Manabu
Middle name
Last name Mogitate

Organization

Mogitate ENT Clinic

Division name

Mogitate ENT Clinic

Zip code

2130011

Address

4F-401, Sekiguchi Daiichi Building, 1-2-5 Hisamoto, Takatsu-ku, Kawasaki-shi, Kanagawa, Japan

TEL

0448654187

Email

mogitateentjp@m08.itscom.net


Public contact

Name of contact person

1st name Manabu
Middle name
Last name Mogitate

Organization

Mogitate Medical Corporation

Division name

Mogitate ENT Clinic

Zip code

2130011

Address

4F-401, Sekiguchi Daiichi Building, 1-2-5 Hisamoto, Takatsu-ku, Kawasaki-shi, Kanagawa, Japan

TEL

0448654187

Homepage URL


Email

mogitateentjp@m08.itscom.net


Sponsor or person

Institute

Medical Corporation Mogitate (Mogitate ENT Clinic)

Institute

Department

Personal name

Manabu Mogitate


Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board: Ota General Hospital Ethics Committee

Address

1-50 Nisshin-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan

Tel

0442440131

Email

info@ota-g-hospital.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 05 Month 18 Day

Date of IRB

2026 Year 05 Month 21 Day

Anticipated trial start date

2026 Year 06 Month 01 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

No additional information


Management information

Registered date

2026 Year 05 Month 28 Day

Last modified on

2026 Year 05 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070645